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and Neurodegeneration:
The Chicken or the Egg?
insoluble amyloid and tau deposition are present, the
temporal or causal relationship between the cascade of
amyloid deposition or tau aggregation and the relation-
ship of both of these processes to cell death and dys-
function remain as gaping holes in our understanding.
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NFTs seen in patients’ brains are intracellular depositsDavid Geffen School of Medicine
composed of insoluble, hyperphosphorylated tau in aUniversity of California, Los Angeles
filamentous form, classically the paired helical (PHF),710 Westwood Plaza
ribbon-like, or straight filament. Normally, tau is distrib-Los Angeles, California 90095
uted extensively and MT associated in axons, but when
hyperphosphorylated in its pretangle form, its affinity
for MTs is significantly reduced and it becomes prefer-Pathological aggregation of the microtubule-associ-
entially located in the somatodendritic compartment.ated protein tau is a common feature of many neurode-
Tau self-aggregates in vitro in a concentration-depen-generative diseases. Although tau aggregation is as-
dent manner, forming both straight and paired helicalsociated with abnormal tau phosphorylation, the role
filaments identical to those observed in vivo. This pro-of phosphorylation in the initiation of neurodegenera-
cess of tau polymerization is accelerated by a numbertion has been unclear. Now, several animal models
of factors including polyanionic compounds such asand data from human patients provide converging evi-
glycosaminoglycans and nucleic acids, certain fattydence that aberrant tau phosphorylation can cause a
acids, and hyperphosphorylation (Lee et al., 2001; Bueeneurodegenerative phenotype similar to that seen in
et al., 2000).human neurodegenerative diseases.
Tau phosporylation plays a normal physiologic role in
decreasing tau’s affinity for MTs and is an importantIntroduction
regulator of MT polymerization during development. TauPathologic deposition of the microtubule (MT)-associ-
has approximately 20 to 30 potential phosphorylationated protein tau, in the form of hyperphosphorylated
sites, many of which are putative targets of proline-inclusions or filamentous neurofibrillary tangles (NFTs),
directed serine/threonine kinases. Accumulating evidenceis one of the defining features of adult-onset neurode-
suggests that two such kinases, glycogen synthasegenerative diseases such as Alzheimer’s disease (AD),
kinase-3 (GSK-3) and cyclin-dependent kinase-5progressive supranuclear palsy (PSP), and frontotempo-
(cdk5), are major tau kinases in vitro and in vivo. In AD,ral dementia and parkinsonism linked to chromosome
FTD, and PSP, insoluble PHF tau and its other pathologi-17 (FTDP-17) (reviewed in Lee et al., 2001; Buee et al.,
cally aggregated forms invariably contain tau hyper-2000). Until recently, much of the genetic evidence for
phosphorylated on residues that overlap with GSK-3AD pointed to the generation of amyloid-forming A
and cdk5 targets. However, until recently it has beenpeptides. Hyperphosphorylated insoluble tau in the form
unclear whether aberrant tau phosphorylation by theseof NFTs was considered by many to be a relative by-
or other kinases, such as p42/44 MAP Kinase (MAPK)stander, despite the persistent association of tau depo-
and p38 MAPK (Buee et al., 2000; Lee et al., 2001), cansition with dysfunctional neurons within diseased brains
cause NFT formation in vivo.and cognitive dysfunction in normal aging (e.g., Braak
Tau Hyperphosphorylation Causes or Enhancesand Braak, 1996; Green et al., 2000).
NFT Formation
The identification of highly penetrant, dominantly in-
Evidence from the fly (Wittmann et al., 2001; Jackson
herited mutations in tau causing the related dementia,
et al., 2002) and the mouse (Cruz et al., 2003 [this issue
FTDP-17, demonstrated conclusively that disruption of of Neuron]) suggests that insoluble aggregates such as
tau homeostasis could be a primary cause of neurode- NFTs and amyloid plaques are signposts of damage
generation (Poorkaj et al., 1998; Hutton et al., 1998). already done; tau-related neurodegeneration can occur
FTDP-17 is a clinically and pathologically heterogeneous without, or precede, frank NFT formation. However, pro-
group of disorders that includes Pick’s disease (Lee cesses that accelerate NFT formation inevitably worsen
et al., 2001; Bird et al., 2003). A key feature of these neurodegeneration, supporting the concept that NFTs
conditions is an absence of significant amyloid pathol- mark a critical, albeit probably later, process in disease
ogy. However, while tau deposition in the form of NFTs progression. Previous work has shown that tau hyper-
is a defining feature of AD, no mutations in tau have phosphorylation by GSK-3 in the fly (Jackson et al.,
been identified in AD or sporadic cases of FTD, and tau 2002) and cdk5 in mouse (Noble et al., 2003) can cause
mutations account for only about 15% of inherited FTD or accelerate NFT formation in vivo, with an attendant
cases (Bird et al., 2003; Lee et al., 2001). Therefore, worsening of neurodegeneration. However, these ef-
understanding the factors that lead to the formation of fects were observed on a background of either wt tau
pathological aggregates in the context of nonmutant tau overexpression or expression of a mutant tau transgene,
in AD, FTD, and related neurodegenerative disorders is raising the question of whether significant tau hyper-
of major importance. Additionally, in AD, where both phosphorylation alone under normal conditions may lead
to neurofibrillary tau pathology. If so, perhaps tau ki-
nases become an even more attractive target for thera-*Correspondence: dhg@ucla.edu
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peutic development. Two previous studies of cdk5 dys- and/or accelerated by tau kinase overactivity in vivo
(e.g., Jackson et al., 2002; Noble et al., 2003; Liou et al.,regulation have shown pathologic tau phosphorylation
at the pretangle stage and evidence of disruption of the 2003) and firmly establishes tau phosphorylation as a
potential therapeutic target in AD and FTD.axonal cytoskeleton. But, while previous studies of p35-
25-induced cdk5 overactivity had demonstrated that p25- Recently, Noble et al. (2003) demonstrated that p25/
cdk5 overactivation, in conjunction with expression ofinduced cdk5 activation caused neurodegeneration in
vitro (Patrick et al., 1999), no evidence of NFTs or neuro- human tau containing the most common FTD-causing
mutation in mouse, is associated with concomitant GSK-degeneration was identified in these two mouse models
of p25/cdk5 overexpression (Ahlijanian et al., 2000; Bian 3/ activation. Thus, although p25/cdk5 activation pro-
vides the initial insult in the Noble et al. model, GSK-3et al., 2002).
In this issue of Neuron, Cruz et al. (2003) again exam- is likely to be playing a role. Why GSK-3 activation is
not observed in the model developed by Cruz et al. isine whether cdk5 activation can cause neurofibrillary
pathology and neurodegeneration by overexpressing not known—it may not be relevant in the context of such
high cdk5 activity. The authors propose that GSK-3the cdk5 activator, p25, in the postnatal mouse forebrain
under control of an inducible CamK-II promoter, re- may act to produce NFTs in the context of mutant or
overexpressed tau, rather than normal tau. However,sulting in an approximately 2-fold induction in cdk5 ac-
tivity and increased specificity for pathological sub- the persistent localization of GSK-3with pretangle and
tangle-bearing neurons in human AD suggests oth-strates, such as tau and APP. Between 5 and 12 weeks
after cdk5 induction, a time-dependent decrease in erwise.
Although the circumstantial evidence is strong, it isbrain weight, as well as prominent neuronal loss in the
cerebral cortex, along with astrogliosis and caspase 3 not yet certain whether the neurodegeneration in the
Cruz et al. model of p25 overexpression is a directactivation, was observed. Although there was no overt
change in tau protein expression itself, insoluble patho- consequence of tau hyperphosphorylation by cdk5 or
occurs via another signaling cascade. Cdk5 has manylogic tau with epitopes and conformation similar to that
found in human AD brains was observed to accumulate substrates, including proteins associated with neurode-
generation, such as APP (which are preferentially hyper-in the mice overexpressing p25, demonstrated by a
combination of immunoblotting, mass spectroscopy, phosphorylated by the p25/cdk5 complex; Cruz et al.,
2003; Dhavan and Tsai, 2001). Cdk5 is also involvedand electron microscopy. Despite the clear biochemical
and immunocytochemical evidence of tau hyperphos- in several aspects of neuronal differentiation as a link
between extracellular signals and the cytoskeleton andphorylation followed by its subsequent insolubility and
aggregation, no clear neurofibrillary pathology as evi- thus could lead to cell dysfunction and death via a num-
ber of different pathways. Additionally, Cruz et al. dem-denced by light microscopy, thioflavin-S, or silver stain-
ing was seen at 12 to 16 weeks. However, by 27 weeks onstrate that tau is hyperphosphorylated on sites that
are not known cdk5 targets and that two other knownof cdk5 induction, neurofibrillary-like pathology was
abundantly visible on light and electron microscopy in tau kinases may be activated, suggesting that at least
some of the effects of p25 overactivation are indirect.the cerebral cortex and hippocampus. The ultrastruc-
tural characteristics of these NFTs and their periodicity Whether this indirect effect occurs through activation
of other kinases, by downregulation of phosphatases,have not been characterized, so whether they are or-
thologous to straight filaments or PHF observed in hu- or somehow by altering the affinity of peptidyl-prolyl
isomerases for tau (favoring a conformation not permis-man FTD or AD is unknown. The interpretation of fila-
ment ultrastructure is also complicated by differences sive for tau dephosphorylation) are important issues that
now need to be addressed. Nevertheless, it is becomingin tau isoforms between mice and humans, which could
lead to different filament morphologies. However, the clear that direct or indirect tau hyperphosphorylation
via at least two proline-directed kinases can acceleratephosphorylation pattern, insolubility, and light micro-
scopic appearance described by Cruz et al. are consis- or cause neurodegeneration and NFT formation.
The importance of dephosphorylation in tauopathy istent with these deposits being typical NFTs, and their
distribution correlates with the regional pattern of cdk5 highlighted by the ability of the phosphorylation-depen-
dent prolyl isomerase, Pin1, to provide relative protec-activation. In the future, it will be important to determine
filament ultrastructure and the relationship between be- tion from age-dependent neurodegeneration (Liou et al.,
2003). Pin1 recognizes specific phosphorylated serinehavioral abnormalities and the timing and topology of
neuronal loss and NFT appearance. or threonine residues in tau that are followed by proline
residues and catalyzes a critical conformational changeWhy this model of cdk5 activation produces striking
neurodegeneration and NFT formation, and previous that allows dephosphorylation at these residues to oc-
cur. Pin1 expression is inversely correlated with markersmodels did not, is not known. Cruz et al. suggest that
NFT formation is most likely due to the significantly of neurofibrillary pathology in human AD brains, and
Pin/ mice develop tau hyperphosphorylation, NFTs,greater cdk5 activation present in this model relative to
previous models. The differences in promoters used in and age-dependent neurodegeneration (Liou et al.,
2003). This pathology is very similar to that caused byeach of these models may also be contributory. In any
regard, Cruz et al. provide the strongest evidence to misexpression of either mutant or wt tau in other models
(e.g., Lewis et al., 2001; Allen et al., 2002; Andorfer etdate that aberrant tau kinase activity of any kind can
lead to neurodegeneration and tau neurofibrillary pa- al., 2003), emphasizing that multiple pathways affecting
tau expression levels, dephosphorylation (e.g., Kins etthology in vivo in the absence of tau dysregulation or
mutations. These findings add to a growing body of al., 2001), and phosphorylation may coalesce in a com-
mon phenotype characterized by tau hyperphosphoryla-evidence that NFTs or NFT-like pathology can be caused
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Figure 1. Tau Aggregation and Neurodegen-
eration: The Balance of Tau Phosphorylation
Tau is tightly balanced between being MT
bound or free, depending on the state of the
cell. Factors that promote an increase in un-
bound tau and aggregation are highlighted
with red arrows (e.g., tau kinases), and pro-
tective factors are blue (e.g., tau phospha-
tases). This model focuses on a toxic gain-
of-function mechanism based on increased
tau aggregation and depicts cdk5 as acting
upstream of GSK-3. Loss of function, such
as cytoskeletal disruption based on tau hy-
perphosphorylation and MT dysregulation,
may contribute as well. Genetic and environ-
mental factors may act at many steps. For
example, tau mutations lead to increased free
tau or tau isoforms that may be more prone
to aggregate, whereas ApoE may act on A42
and Tau. For many of the tauopathies, such
as FTD, this process occurs independently
of A42.
tion, aggregation, and NFT formation. Current evidence understanding and treatment of these neurodegenera-
tive diseases. (1) How might these pathways involvingshows that the known FTDP-17-causing tau mutations
either disrupt MT binding or affect tau splicing, leading tau intersect with the amyloid cascade that is proposed
to lead to neurodegeneration in AD? (2) Do any of theseto tau isoform imbalance (Lee et al., 2001; Hutton et al.,
1998). Therefore, one feature potentially in common with processes or mechanisms explain the regional vulnera-
bility that is the hallmark of human neurodegenerativethe human mutations and animal models of tauopathy
is an increase in free tau unbound to microtubules. Since diseases, such as FTD and AD? With regard to the first
question, current evidence supports that view that Atau polymerization into filaments is concentration de-
pendent in vitro, this provides an obvious common could lie upstream of tau in AD, since increased A42
leads to increased neurodegeneration and NFTs inmechanism for tau aggregation and NFT formation in
vivo (Figure 1). mouse models carrying FTDP-17 causing tau mutations.
We have previously speculated that GSK-3 could po-This of course begs several questions: is there a com-
mon mechanism that leads to neurodegeneration in tentially mediate this toxic effect of amyloid (Jackson
et al., 2002). Fibrillar A42 fragments induce GSK-3these different models of tauopathy, whether the model
is based on tau misexpression, mutation, or altered ki- activation in vitro, leading to tau phosphorylation and
apoptosis. Other kinases such as p38 MAPK, p42/44nase activity? The pervasive association of tau insolubil-
ity, the common pattern of pathological tau phosphory- MAPK, and CDK5 may play similar roles (Lee et al., 2000;
Zheng et al., 2002). This cascade of kinase induction bylation, and the histological signs of tau deposition
observed in these models suggest that this is the case, A42 could be a particularly vicious circle, as at least
one form of GSK3 is involved in A42 production (Phielbut it is not certain. Perhaps, most relevant to the current
discussion, are cdk5, GSK-3, and other tau kinases et al., 2003). In the case of sporadic disease, it is also
equally plausible that genetic and environmental factorsacting in series or in parallel? The recent paper by Noble
et al. (2003) and in vitro evidence suggest that cdk5 that increase amyloid deposition, such as ApoE iso-
forms, oxidative stress, etc., also induce tau aggregationcould be upstream of GSK-3, serving to prime tau at
key epitopes that modulate tau’s affinity for microtu- or hyperphosphorylation, and the two aggregation path-
ways are initiated concurrently for AD, or alone, as wouldbules. This hypothesis can be tested in vivo, since the
detrimental effects of GSK-3 should be attenuated on be the case in FTD.
One of the most constant features of AD and FTDa background of conditional cdk5 inactivation. Further-
more, specific kinase inhibitors can be tested to assess are their distinct clinical presentations, which reflect the
distinct early regional pathology in these disorders. Wetheir ability to modulate the pathology observed in ani-
mals with mutant tau transgenes to test the primacy of have speculated that this regional vulnerability in FTD
may have a developmental component that alters neu-particular kinase or phosphatase pathways. Of course,
all of these mechanisms being studied in animal models ronal patterning or phenotype generation in a manner
that would render that region more susceptible to theneed to be considered from the perspective of their
potential overlap with the pathological alterations ob- later insults of aging (Geschwind and Miller, 2001).
Genes with a dual role in patterning and neurodegenera-served in human subjects (e.g., Patrick et al., 1999; Liou
et al., 2003). tion could contribute to the focal nature of these disor-
ders, and both cdk5 and GSK3 have important roles inTau, Amyloid, and Regional Vulnerability
Finally, it is necessary to consider tau phosphorylation CNS patterning and development outside of their role
as tau kinases (Anderton et al., 2000).in the context of two issues that seem central to our
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